Spark NIR™ 685 anti-human CD19 Antibody

Product Details

Reactivity

Human

Antibody Type

Monoclonal

Host Species

Mouse

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)

Preparation

The antibody was purified by affinity chromatography and conjugated with Spark NIR™ 685 under optimal conditions.

Concentration

Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)

Storage & Handling

The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.

Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µL per million cells in 100 µL staining volume or 5 µL per 100 µL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

* Spark NIR™ 685 has a maximum excitation of 665 nm and a maximum emission of 685 nm.

Excitation Laser

Red Laser (633 nm)

Application Notes

Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue sections⁸ and blocking of B cell proliferation. Clone HIB19 is not recommended for formalin-fixed paraffin-embedded sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 302267 & 302268).

 

Clone HIB19 partially blocks anti-human CD19 clones 4G7 and SJ25C1 staining based on in-house testing

Application References

(PubMed link indicates BioLegend citation)

1. Schlossman S, et al. 1995. Leucocyte Typing V. Oxford University Press. New York.
2. Knapp W, et al. 1989. Leucocyte Typing IV. Oxford University Press. New York.
3. Bradbury L, et al. 1993. J. Immunol. 151:2915.
4. Joseph A, et al. 2010. J. Virol. 84:6645. PubMed
5. Wang X, et al. 2010. Haematologica. 95:884. (FC) PubMed
6. Walker JD, et al. 2009. J. Immunol. 182:1548. (Block) PubMed
7. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
8. Hansen A, et al. 2002. Arthritis Rheum. 46:2160. (IHC)
9. Stoeckius M, et al. 2017. Nat. Methods. 14:865. (PG)
10. Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG)

Product Citations

1. Szabo PA, et al. 2021. Immunity. 54(4):797-814.e6. PubMed
2. Yu C, et al. 2021. Med (N Y). 2:755. PubMed
3. Lozano-Rodríguez R, et al. 2022. Cell Rep. 38:110235. PubMed
4. Högelin KA, et al. 2021. iScience. 24:103078. PubMed
5. Ogishi M, et al. 2022. J Exp Med. 219:. PubMed
6. Ogishi M, et al. 2023. J Exp Med. 220: . PubMed
7. Xu Q, et al. 2023. Nat Immunol. 24:186. PubMed

RRID

AB_2860769 (BioLegend Cat. No. 302269)
AB_2832581 (BioLegend Cat. No. 302270)

Antigen Details

Structure

Ig superfamily, type I transmembrane glycoprotein, 95 kD

Distribution

B lineage (except plasma cells), follicular dendritic cells

Function

B cell activation and differentiation

Ligand/Receptor

Forms complex with CD21 (CR2) and CD81 (TAPA-1), BCR coreceptor

Cell Type

B cells, Dendritic cells

Biology Area

Costimulatory Molecules, Immunology

Molecular Family

CD Molecules

Antigen References

1. Tedder T, et al. 1994. Immunol. Today 15:437.
2. Bradbury L, et al. 1993. J. Immunol. 151:2915.

Gene ID

930 View all products for this Gene ID

UniProt

View information about CD19 on UniProt.org

Documentation

• Technical Data Sheet (pdf)
• Certificate of Analysis
• Safety Data Sheet

Reviews

Related Pages & Pathways

Related FAQs

Other Formats

Concentration & Expiration Lookup

Certificate of Analysis